Index Options
State Street
CME Group
Nasdaq
Cboe
TradingView
Wall Street JournalNews
SPRC
2.750
+3.00%
0.080
Weekly Report: what happened at SPRC last week (1027-1031)?
Weekly Report · 4d ago
N2OFF completes merger with MitoCareX Bio
TipRanks · 10/30 13:32
N2OFF COMPLETED MERGER WITH CANCER DRUG DISCOVERY COMPANY TARGETING TOUGH-TO-TREAT PANCREATIC AND LUNG CANCERS
Reuters · 10/30 13:25
SciSparc’s Promising Clinical Study on SCI-210 for Autism Spectrum Disorder
TipRanks · 10/27 18:06
SciSparc’s SCI-110 Study: A Potential Game-Changer for Tourette Syndrome
TipRanks · 10/27 18:06
Weekly Report: what happened at SPRC last week (1020-1024)?
Weekly Report · 10/27 10:11
SciSparc Completes Sale of MitoCareX to N2OFF, Enhancing Cancer Drug Discovery
TipRanks · 10/24 20:29
N2off Inc. Discloses SciSparc Ltd. as 10% Owner in Initial Beneficial Ownership Filing
Reuters · 10/24 20:06
SciSparc closes acquisition of controlling interest in Neurothera Labs
TipRanks · 10/24 12:00
SciSparc Closes Acquisition and Gains Control of Neurothera Labs
Reuters · 10/24 11:55
SciSparc Announces Closing of the Acquisition of a Publicly Traded Company on the TSXV to which it transferred its Advanced Clinical Stage Pharmaceutical Portfolio
Barchart · 10/24 06:55
SciSparc Closes Sale of MitoCareX to N2OFF
Reuters · 10/23 20:03
SCISPARC ANNOUNCES CLOSING OF THE SALE TO N2OFF OF MAJORITY-OWNED SUBSIDIARY MITOCAREX, ADVANCING DRUG DISCOVERY FOR RESISTANT CANCERS INCLUDING PANCREATIC AND NON-SMALL CELL LUNG CANCER
Reuters · 10/23 20:03
N2OFF Closes Merger with MitoCareX Bio
Reuters · 10/23 20:02
Psychedelic: Clearmind enrolls last patient in first cohort of CMND-100 trial
TipRanks · 10/23 15:20
SciSparc targets quantum-powered 3D protein modeling technology
TipRanks · 10/23 13:00
SciSparc Launches Quantum 3D Protein Modeling Initiative for AI Drug Discovery
Reuters · 10/23 12:55
N2OFF Closes Merger With MitoCareX Bio, Expanding Into Cancer Drug Discovery Targeting The Mitochondrial SLC25 Protein Family
Benzinga · 10/23 12:26
SciSparc Targets Quantum-Powered 3D Protein Modeling Technology to Revolutionize AI Drug Discovery
Barchart · 10/23 07:55
SciSparc and Clearmind’s New Patent Targets Binge Behavior Disorders
TipRanks · 10/20 18:24
More
Webull provides a variety of real-time SPRC stock news. You can receive the latest news about Scisparc through multiple platforms. This information may help you make smarter investment decisions.
About SPRC
Scisparc Ltd, former Therapix Biosciences Ltd is a Israel-based pharmaceutical company commited into creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The company is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.